Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,242,505
  • Shares Outstanding, K 125,070
  • Annual Sales, $ 124,900 K
  • Annual Income, $ -289,400 K
  • 36-Month Beta 3.36
  • Price/Sales 17.95
  • Price/Cash Flow N/A
  • Price/Book 10.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.56
  • Number of Estimates 6
  • High Estimate -0.54
  • Low Estimate -0.59
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -1.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.81 +5.12%
on 11/27/18
21.03 -15.98%
on 11/29/18
+0.14 (+0.80%)
since 11/14/18
3-Month
13.87 +27.40%
on 09/17/18
23.55 -24.97%
on 11/02/18
+3.79 (+27.31%)
since 09/14/18
52-Week
12.77 +38.37%
on 08/09/18
32.99 -46.44%
on 01/29/18
-11.30 (-39.01%)
since 12/14/17

Most Recent Stories

More News
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central...

ACAD : 17.67 (-1.45%)
Acadia Pharmaceu has the Best Relative Performance in the Biotechnology Industry (ACAD , ARWR, LXRX , NTRA , EXAS )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

LXRX : 7.26 (+2.40%)
ARWR : 14.32 (-3.24%)
ACAD : 17.67 (-1.45%)
After Yesterday's Decline of 10.05%, Acadia Pharmaceu Offers Investors Better Value

Acadia Pharmaceu (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $17.33 to a high of $18.35. Yesterday, the shares fell 10.0%, which took the trading range below the 3-day low of...

ACAD : 17.67 (-1.45%)
Today's Research Reports on Trending Tickers: Novavax and ACADIA Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet),...

ACAD : 17.67 (-1.45%)
NVAX : 2.41 (+4.78%)
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central...

ACAD : 17.67 (-1.45%)
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 13.79% and 0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 17.67 (-1.45%)
Acadia: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Tuesday reported a loss of $62.1 million in its third quarter.

ACAD : 17.67 (-1.45%)
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

---Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder

ACAD : 17.67 (-1.45%)
NEU : 394.11 (-0.06%)
Acadia Pharmaceu Has Returned 26.9% Since SmarTrend Recommendation (ACAD)

SmarTrend identified an Uptrend for Acadia Pharmaceu (NASDAQ:ACAD) on September 20th, 2018 at $17.11. In approximately 2 months, Acadia Pharmaceu has returned 26.91% as of today's recent price of $21.72....

ACAD : 17.67 (-1.45%)
Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Shares of Tonix Pharmaceuticals were flying higher in Wednesday's session on news that the company plans to start a new Phase 3 trial of Tonmya, a drug formulation...

TNXP : 2.81 (+2.93%)
ACAD : 17.67 (-1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade ACAD with:

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

2nd Resistance Point 18.54
1st Resistance Point 18.11
Last Price 17.67
1st Support Level 17.40
2nd Support Level 17.12

See More

52-Week High 32.99
Fibonacci 61.8% 25.27
Fibonacci 50% 22.88
Fibonacci 38.2% 20.49
Last Price 17.67
52-Week Low 12.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar